Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University Health Network
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 7, 2025
Product Development
The radiopharma landscape takes shape in neuroendocrine tumors
Itm and Perspective’s readouts are the latest clinical advances in GEP-NETs, the first indication to put radioligand therapies on the map
BioCentury | Apr 29, 2022
Discovery & Translation
Neoantigen-reactive T cell signatures; plus CAR T cell therapy improvements and more
BioCentury’s roundup of translational news
BioCentury | Jun 24, 2021
Finance
Funding roundup: F-Prime leads series A for Toronto Dx company Adela; plus fresh funding for Strand, Tvardi, Orum, Glycomine and HutchMed
Meanwhile, digital biotech Pear readies for SPAC
BioCentury | Oct 9, 2020
Deals
Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna
Kronos raises $250M in NASDAQ IPOLook for shares of Kronos Bio Inc. (NASDAQ:KRON) to begin trading on Friday after the company raised $250 million in an IPO. The listing completes a busy few months
BioCentury | Jan 14, 2020
Company News
Treadwell emerges with two clinical cancer compounds, $27M seed from Tio
BioCentury | Dec 6, 2019
Targets & Mechanisms
Emerging immuno-oncology mechanisms at ASH 2019
Immune system biomarkers take center stage among emerging targets at ASH 2019
BioCentury | Sep 19, 2019
Preclinical News
Sept. 19 Preclinical Quick Takes: Celsius' single-cell analysis; plus Merck's RSV therapy, glial cell transplant and methylation profiles for tumors
BioCentury | Apr 12, 2019
Emerging Company Profile
Bright Angel: New hope against fungal resistance
How Bright Angel's HSP90 inhibitor could block antifungal resistance
Items per page:
1 - 10 of 76